Guardant Health, Inc. (NASDAQ:GH) Given Average Rating of “Buy” by Brokerages

Guardant Health, Inc. (NASDAQ:GH) has been assigned an average rating of “Buy” from the sixteen analysts that are covering the stock, Marketbeat.com reports. Sixteen analysts have rated the stock with a buy rating. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $42.63.

A number of brokerages recently weighed in on GH. Leerink Partners decreased their price objective on shares of Guardant Health from $60.00 to $50.00 and set an “outperform” rating for the company in a research note on Thursday, October 17th. Barclays assumed coverage on Guardant Health in a research note on Thursday, January 23rd. They set an “overweight” rating and a $60.00 price target for the company. The Goldman Sachs Group lifted their price target on shares of Guardant Health from $36.00 to $49.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Sanford C. Bernstein lowered their price objective on shares of Guardant Health from $40.00 to $35.00 and set an “outperform” rating for the company in a research note on Wednesday, October 30th. Finally, Guggenheim reiterated a “buy” rating on shares of Guardant Health in a report on Wednesday, January 22nd.

Insiders Place Their Bets

In other Guardant Health news, Director Meghan V. Joyce sold 2,896 shares of the business’s stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $29.90, for a total transaction of $86,590.40. Following the sale, the director now directly owns 7,648 shares in the company, valued at approximately $228,675.20. The trade was a 27.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Musa Tariq sold 2,320 shares of the business’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $35.00, for a total value of $81,200.00. Following the completion of the sale, the director now directly owns 2,676 shares in the company, valued at $93,660. This represents a 46.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,548 shares of company stock valued at $179,782 over the last quarter. Insiders own 5.50% of the company’s stock.

Institutional Trading of Guardant Health

A number of hedge funds have recently bought and sold shares of the company. Arizona State Retirement System raised its holdings in shares of Guardant Health by 1.1% during the 4th quarter. Arizona State Retirement System now owns 35,639 shares of the company’s stock valued at $1,089,000 after purchasing an additional 403 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Guardant Health by 21.8% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company’s stock worth $102,000 after purchasing an additional 796 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in Guardant Health by 43.5% during the 4th quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after purchasing an additional 817 shares in the last quarter. Fiduciary Alliance LLC raised its stake in shares of Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company’s stock worth $363,000 after acquiring an additional 836 shares during the last quarter. Finally, R Squared Ltd bought a new position in shares of Guardant Health in the 4th quarter valued at about $26,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Stock Down 0.2 %

Shares of GH opened at $44.40 on Tuesday. Guardant Health has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The company has a market cap of $5.49 billion, a P/E ratio of -10.47 and a beta of 1.32. The firm’s 50 day moving average price is $38.30 and its 200 day moving average price is $30.74.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.